A former Fellow in Infectious Disease at Harvard Medical School and current member of the American College of Physicians, Robert Hindes, MD, brings a substantial amount of experience to bear in researching and treating infection from the hepatitis C virus. In addition to serving as the chief medical officer at Trek Therapeutics, PBC, Robert Hindes, MD, regularly submits articles to several medical journals for publication.
In 2013, Dr. Hindes co-authored 2 research articles to The Lancet Infectious Diseases:
– Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial
– Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial
A medical journal that published its first issue in 1823, The Lancet Infectious Diseases is a weekly journal founded by Thomas Wakley. One goal of the journal is to make science globally available so that medicine can have the greatest impact on people’s lives.
Toward this end, The Lancet Infectious Diseases is governed by its manifesto, which includes setting high standards and selecting only the highest quality research papers, selecting only research that has the ability to improve people’s lives, and increasing the social impact of science through development and exposure to the public. For additional information on the journal, visit www.thelancet.com/about-us.